The substantial safety improvement and trial amendment to a registrational path are significant catalysts. Monitor for additional Phase 1 data and End-of-Phase 1 FDA meeting in H2 2026, which could de-risk LYL273's regulatory pathway and support a pivotal trial start.
LYEL drugs
LYEL drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 8 $12.31entry
- T+1 · 5mo ago +3.17%α +3.46% · $12.70
- T+5 · 5mo ago +10.07%α +7.96% · $13.55
- T+20 · 4mo ago +14.05%α +12.42% · $14.04
- T+60 · 3mo ago +17.99%α +14.94% · $14.53
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lyell Immunopharma announced updated safety data from its Phase 1 trial of LYL273 in metastatic colorectal cancer, showing GI prophylaxis reduced Grade ≥2 diarrhea/colitis from 55% to 10%. The trial was amended to a Phase 1/2 design enabling a potential pivotal single-arm Phase 2 trial, with an End-of-Phase 1 FDA meeting and additional clinical data expected in H2 2026.
Key Facts
- GI prophylaxis reduced Grade ≥2 diarrhea/colitis from 55% (without prophylaxis, N=9) to 10% (with prophylaxis, N=10).
- No Grade ≥3 CRS or ICANS observed in patients receiving GI prophylaxis.
- Maximum tolerated dose has not yet been determined; dose escalation continues.
- Phase 1 trial amended to Phase 1/2 design (CARABINER) enabling seamless expansion into a potential pivotal single-arm Phase 2 trial.
- New cohorts added: second-line cohort and combination with radiotherapy; up to 60 patients expected across new cohorts.
- End-of-Phase 1 FDA meeting and additional Phase 1 clinical data expected in H2 2026.
- LYL273 has FDA Fast Track designation for mCRC.
- Previously reported 50% overall response rate across Dose Levels 1 and 2 (data cutoff Oct 28, 2025) in 3L+ mCRC.
Financial Impact
No financial figures disclosed; early-stage clinical data with no revenue or deal value.
Risk Factors
- Maximum tolerated dose not yet determined; dose escalation could reveal unexpected toxicity.
- Phase 2 regulatory alignment with FDA is pending and not guaranteed.
- Small sample size (N=19) limits statistical reliability of safety and efficacy data.
- Solid tumor CAR-T remains a challenging field with high historical failure rates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307886 |
Track record
21 reports on LYEL
4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +13.54% at T+1 after the Mar 6, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
- Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
- Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
- Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers